Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Sprout Health Partners LLC dba Sprout Health
WARNING LETTER
•Sprout Health Partners LLC dba Sprout Health•August 31, 2025

Sprout Health Partners LLC dba Sprout Health – FDA Warning Letter, Aug 31, 2025

Record Details

The FDA issued a warning letter to Sprout Health on September 9, 2025, following a review of their website in August 2025. The review identified that Sprout Health"s website offers compounded drug products, including semaglutide and tirzepatide, with claims that are false or misleading under the Federal Food, Drug, and Cosmetic Act (FDCA). Specifically, the claims imply that these compounded products are equivalent to FDA-approved products, which they are not, leading to their classification as misbranded under sections 502(a) and 502(bb) of the FDCA.

The FDA highlighted that the introduction or delivery of these misbranded products into interstate commerce violates section 301(a) of the FDCA. The letter emphasizes that the violations noted are not exhaustive, and Sprout Health is responsible for identifying and correcting all violations to ensure compliance with federal law. Immediate corrective actions are required, including ceasing misleading claims.

Sprout Health must respond within 15 working days, detailing steps taken to address the violations and prevent recurrence. Failure to comply may result in legal actions, including seizure or injunction. The letter also notes that if Sprout Health operates outside the U.S., their products may be detained or refused entry into the U.S. The FDA encourages Sprout Health to provide reasoning and supporting information if they believe their products are not in violation. Correspondence should be directed to the Office of Compounding Quality and Compliance.

Company
Sprout Health Partners LLC dba Sprout Health
Inspection date
August 31, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • George Tidmarsh (Director)
View Company Profile

ID · ebbc005d-2e88-477d-9877-a9c6e85b9356

Violation Codes10
21 U.S.C. 321(g)FD&C Act 502(b)21.U.S.C. 331(a)21 U.S.C. 352(a)FD&C Act 301(c)FD&C Act 201(p)21 U.S.C. 352(bb)21 U.S.C. 331(c)21 U.S.C. 321(p)FD&C Act 502(a)

Full citation text and observation details available on the Dashboard.

Other documents for Sprout Health Partners LLC dba Sprout Health
  • WARNING_LETTER - 2025-08-01August 1, 2025

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Sprout Health Partners LLC dba Sprout Health
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.